linjc16/ctgov huggingface dataset:
Relationship Between Dietary Protein Intake and Fatal and Non-fatal Health Outcomes

Study Overview
=================
Brief Summary
-----------------
The aim of the current study was to clarify the relationship between protein intake and health by using a very large, general population cohort study, UK Biobank, to study the associations between reported protein intake (expressed in g/day, g/kg/day and % of total energy intake) and three health outcomes (all-cause mortality, incidence CVD and cancer).

Official Title
-----------------
Relationship Between Dietary Protein Intake and Fatal and Non-fatal Health Outcomes in 180,031 UK Biobank Participants

Conditions
-----------------
Cardiovascular Diseases, Cancer, All-cause Mortality

Intervention / Treatment
-----------------
* Other: None as this is an observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: None Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: None as this is an observational study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | Date and cause of death were obtained from death certificates | Mean of 7 years | 
| CVD incidence | Date and cause of hospital admissions were identified via record linkage to Health Episode Statistics (HES) records for England and Wales and to the Scottish Morbidity Records (SMR01) for Scotland | Mean of 6.1 years | 
| cancer incidence | Data on cancer diagnoses for participants resident in England and Wales is provided to UK Biobank by the Medical Research Information Service, based at the National Health Service Information Centre (http://www.ic.nhs.uk/services/medical-research-informationservice). The Information Services Division (http://www.isdscotland.org/HealthTopics/Cancer/), which is a part of NHS Scotland, provides UK Biobank with the cancer data records for participants resident in Scotland. | Mean of 6.1 years |
Exploration of Angiogenesis in Decompensated Developmental Venous Abnormalities

Study Overview
=================
Brief Summary
-----------------
The purpose of our study is to demonstrate by blood samples in situ in the vascular lesion (performed during any cerebral catheterization for an embolization of arteriovenous malformation) the existence of angiogenic growth factors and inflammatory factors that would confirm the decompensation of venous ischemia.

Official Title
-----------------
Exploration of Angiogenesis in Decompensated Developmental Venous Abnormalities

Conditions
-----------------
Developmental Venous Anomaly

Intervention / Treatment
-----------------
* Procedure: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Presenting a DVA requiring hyperselective catheterization Having sign an informed consent form Exclusion Criteria: Presenting a contraindication to the realization of hyperselective cathterism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blood sample<br>Blood sampling Under general anesthesia | Procedure: Blood sampling<br>* Blood sampling under general anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of angiogenic and inflammatory growth factors | The 1st factor studied is VEGF-A | 1 day | 
| Assessment of angiogenic and inflammatory growth factors | The 2nd factor studied is VEGF-A | 1 day | 
| Assessment of angiogenic and inflammatory growth factors | The 3rd factor studied is angiopoitin-2 | 1 day | 
| Assessment of angiogenic and inflammatory growth factors | The 4th factor studied is PDGF | 1 day | 
| Assessment of angiogenic and inflammatory growth factors | The 5th factor studied is angiopoietin-like 4 | 1 day |
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Study Overview
=================
Brief Summary
-----------------
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Official Title
-----------------
Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment

Conditions
-----------------
Dyslipidemia, Renal Insufficiency

Intervention / Treatment
-----------------
* Drug: ABT-335
* Drug: Rosuvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Body Mass Index (BMI) 19 to 33, inclusive Either normal kidney function, or mild or moderate kidney impairment Exclusion Criteria Use of any medications, vitamins and/or herbal supplements within 2 weeks prior to study drug administration, except those required for management of renal disease. History of epilepsy, any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: ABT-335<br>* 45 mg once daily for 10 consecutive days<br>Drug: Rosuvastatin<br>* 10 mg once daily for 10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin |  | Days 1, 8, 9, and 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of the study drugs |  | Study duration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyslipidemia
SEBBIN Silicone Gel-filled Testicular Implants

Study Overview
=================
Brief Summary
-----------------
This study is part of the clinical evaluation of SEBBIN silicone gel-filled testicular implants, included in the technical file of the device. The aim of the study is to gather additional data about the safety and effectiveness of the device.

Official Title
-----------------
Prospective Observational Study About SEBBIN Silicone Gel-filled Testicular Implants

Conditions
-----------------
Complication, Prosthesis Durability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient is an adult or a child at the time of implant placement with SEBBIN implant. The patient is candidate to a unilateral or bilateral testicular implant placement with SEBBIN implant. The patient has been informed of the study, has read the patient information letter and -provided oral consent. Exclusion Criteria: The patient has silicone implants somewhere else than in the scrotal sac. The patient was diagnosed with one of the following pathologies: Systemic lupus erythematous, Sjogren syndrome, scleroderma, polymyositis, or any other connective tissue disease. Rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, or any other inflammatory arthritic disease. Arthritis, fibromyalgia, chronic fatigue syndrome, or any other mechanic or degenerative non-inflammatory rheumatic disease. The patient has a pathology that could delay healing. Custom-designed implants are used for surgery.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication rate |  | At 10 years of follow-up |
Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
In this study, the microbiota sequencing was used to investigate the changes of microbiota in the terminal ileum and the middle part of ascending colon, the mesenteric adipose tissue of ileum and ascending mesocolon, and oral cavity of patients with Crohn's disease before and after ileocecal resection, so as to further explore the role of ileocecal region in inducing remission of disease.

Official Title
-----------------
Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease

Conditions
-----------------
Crohn Disease, Microtia, Ileocecal; Lesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Crohn's disease Exclusion Criteria: Serious oral diseases (e.g. dental caries, periodontal disease) Other acute or chronic gastrointestinal diseases Probiotics or prebiotic consumption and antibiotic use within 1 month
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Before ileocecal resection<br>Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients were admitted for right hemicolectomy | |
| After ileocecal resection<br>Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients underwent reversal of ileostoma after right hemicolectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbial changes of intestinal mucosa | Explore the microbial changes in the mucosa of the terminal ileum and the middle segment of the ascending colon in patients with Crohn's disease before and after ileocecal resection through metagenomic analysis | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbial changes of mesenteric adipose tissue | Explore the microbial changes in the mesenteric adipose tissue of the terminal ileum and the middle segment of the ascending colon in patients with Crohn's disease before and after ileocecal resection through metagenomic analysis | 6 month |
WT1 Peptid Vaccination in Carcinomas

Study Overview
=================
Brief Summary
-----------------
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Official Title
-----------------
Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas

Conditions
-----------------
WT1 Expressing Carcinoma

Intervention / Treatment
-----------------
* Biological: WT1 126-134 peptide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metastatic cancer, no standard treatment option Resected cancer with minimal residual disease, no standard treatment option WT-1 expression HLA-A2 Exclusion Criteria: Concurrent chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: WT1 126-134 peptide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune response |  |  | 
| Safety |  |  |
Evaluation of Antihypertensive Drugs in OSA Patients

Study Overview
=================
Brief Summary
-----------------
This prospective cohort study aimed to assess the phenotypic characteristics of OSA patients and their pattern of antihypertensive drugs consumption. The investigators also aimed to investigate a hypothetical association between ongoing anti-hypertensive regimen and Blood pressure control rates in these patients. Additionally, the investigators were also interested in trying to understand if the control of OSA may be influenced by the use of different classes of anti-hypertensive drugs.

Official Title
-----------------
Evaluation of Antihypertensive Drugs in Patients With Obstructive Sleep Apnea

Conditions
-----------------
Hypertension, Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged above 18 years, that attended a first visit at CHLN Hospital Sleep Unit were enrolled Exclusion Criteria: severe psychiatric disease or inability to understand the information required for an informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with uncontrolled BP before CPAP (Continuous Positive Airway Pressure) adaptation. |  | patients will be followed up for an expected average time of 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obstructive sleep apnea, hypertension, antihypertensive drugs
Transplantation for Patients With Chronic Lymphocytic Leukemia

Study Overview
=================
Brief Summary
-----------------
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Detailed Description
-----------------
To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Official Title
-----------------
Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia

Conditions
-----------------
Leukemia, Lymphocytic, Chronic

Intervention / Treatment
-----------------
* Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
* Procedure: ablative allogeneic hematopoietic cell transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- adequate organ function normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease For autologous patients more than 30% bone marrow involvement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: high dose chemotherapy then autologous hematopoietic cell transplant|nan|
|Procedure: ablative allogeneic hematopoietic cell transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility |  |  | 
| Toxicity |  |  | 
| olymerase Chain Reaction (PCR) for minimal residual disease |  |  |
Stability of Middle Molecule Clearance

Study Overview
=================
Brief Summary
-----------------
The investigators aim to show, whether all middle molecules are included in the clearance and whether this clearance is stable until 72 hours.

Detailed Description
-----------------
A better middle molecule clearance has been shown until 24 hours of duration. The investigators will extend our observations until 72 hours.

Official Title
-----------------
Long-time Stability of Middle Molecule Clearance During CI-Ca CVVHD

Conditions
-----------------
Continuous Hemodialysis

Intervention / Treatment
-----------------
* Device: Hemodialysis with EMIC 2 filters


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent age>18 years acute renal insufficiency with indication for continuous hemodialysis, according to RILFE classification F: serum creatinine increase > 3-fold or serum creatinine > 4mg/dl with acute increase of >0,5mg/dl Urine Output <0,3mg/kg/h for 24 h or anuria for 12 h body weight:60-80kg anticoagulation with citrate possible and indicated Dose for hemodialysis of 2l/h Exclusion Criteria: participation in another clinical trial within on month prior to this study pregnancy or brest feeding septic shock interference with cystatin-C haemolysis <1g/dl Bilirubin<9mg/dl Triglyceride >700mg/dl rheumatoid factor > 300kIU/l

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EMIC 2 dialysis<br>Patients on ICU requiring dialysis for acute renal insufficiency | Device: Hemodialysis with EMIC 2 filters<br>* Patients with indication for routine continuous hemodialysis due to acute renal insufficiency<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance of Urea |  | up to 72 h | 
| Clearance of Cystatin C |  | up to 72 h | 
| Clearance of creatinine |  | up to 72 h | 
| Clearance of Beta2-Microglobulin |  | up to 72 h | 
| Clearance of Osteocalcin |  | up to 72 h | 
| Free light chains kappa of Immunoglobulins |  | up to 72 h | 
| Clearance of albumin |  | up to 72 h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean arterial pressure |  | up to 72 h | 
| Vasopressor requirement |  | up to 72 h | 
| Heart rate |  | up to 72 h |
Attention Training Trial

Study Overview
=================
Brief Summary
-----------------
This study aims to examine the effects of smartphone-based Attention-Bias Modification Training (ABMT) in chronic pain participants.

Official Title
-----------------
Mobile Based Attention Bias Modification Training for Chronic Pain

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Behavioral: Attention Modification Training
* Behavioral: No Attention Modification Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: existing chronic pain condition Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Attention Modification Training<br>ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful | Behavioral: Attention Modification Training<br>* Subjects are taught to disengage attention from a certain stimuli<br>|
| Placebo Comparator: No Attention Modification Training<br>There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen. | Behavioral: No Attention Modification Training<br>* Subjects are exposed to two stimuli, but attention is not manipulated in any way<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain intensity | questionnaire (numerical pain rating scale) | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain interference | questionnaire (pain interference scale) | 1 hour |